Case Report: Replacement of PD-1 inhibitors with PD-L1 inhibitors in the treatment of squamous non-small-cell lung carcinoma

Frontiers in Immunology

Immunology

Xiaonan Cui¹  Chunxia Zhang¹  Yujun Li¹  Tong Wu¹ 

[1] Department of Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian, China;

关键词: tislelizumab;    cardiotoxicity;    sugemalimab;    PD-L1 inhibitor;    squamous NSCLC;    case report;   

DOI  :  10.3389/fimmu.2023.1243980

 received in 2023-06-21, accepted in 2023-07-26,  发布年份 2023

来源: Frontiers

【 摘 要 】

BackgroundImmune checkpoint inhibitor (ICI)-associated cardiotoxicity is a relatively uncommon immune-related adverse effects (irAEs) with a high mortality rate. There are few recommendations for the replacement of different immune checkpoint inhibitors in domestic and international reports.Case presentationWe report a case of a patient with squamous non-small cell lung carcinoma (squamous NSCLC) who developed cardiotoxicity after being treated with a programmed death-1 (PD-1) inhibitor and then changed to a PD-L1 inhibitor to continue the treatment. A significant benefit was observed after four cycles of immunotherapy, and no further cardiotoxicity occurred after the treatment was started.ConclusionThis case demonstrates that myocardial damage induced by tislelizumab (PD-1 inhibitor) can be improved after switching to sugemalimab (PD-L1 inhibitor) and that antitumor immunotherapy is effective. This result may have important implications for optimizing immunotherapy management regimens in cancer patients.

【 授权许可】

Unknown   
Copyright © 2023 Wu, Li, Cui and Zhang